AUS
NZ
UK
CA
USA
IND
Highlights:
- IDEAYA's IDE275 could become a first-in-class treatment for tumors with microsatellite instability.
- The Phase 1 trial aims to target a significant patient population across several cancer types.
- Potential for substantial financial milestones and royalties tied to IDE275's success.
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a leader in precision medicine for oncology, has recently announced the successful clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). This pivotal milestone allows for the initiation of a Phase 1 clinical trial to evaluate IDE275 (GSK959), a potentially groundbreaking Werner Helicase (WRN) inhibitor. With its robust preclinical efficacy, IDE275 aims to provide targeted treatment options for patients with high microsatellite instability (MSI-High) tumors, including prevalent cancer types such as colorectal, endometrial, and gastric cancers.
IDE275 (GSK959) has garnered attention as a potential first-in-class and best-in-class small molecule inhibitor, discovered through IDEAYA’s collaboration with GlaxoSmithKline (GSK). In preclinical studies, IDE275 demonstrated impressive selective synthetic lethality, particularly in the MSI-High biomarker setting. The clinical trial is set to enroll patients whose tumors exhibit this crucial biomarker, addressing an unmet need in targeted oncology therapies.
Yujiro S. Hata, President and CEO of IDEAYA Biosciences, emphasized the significance of this advancement, stating, “IDE275 represents IDEAYA's fifth potential first-in-class clinical program in our precision medicine oncology pipeline and has a potentially differentiated best-in-class profile.” He further highlighted the promising results observed in preclinical studies, which showed substantial tumor regressions in MSI-High models derived from various cancers. This positions IDE275 as a potential therapeutic option for a notable patient population, as MSI-High tumors account for approximately 31% of endometrial, 20% of colorectal, and 19% of gastric cancers.
The initiation of the Phase 1 trial is anticipated in the fourth quarter of 2024, with GSK serving as the trial sponsor. This trial will explore IDE275’s efficacy both as a standalone treatment and in combination with a PD-1 inhibitor. The collaboration model is notable, with GSK covering 80% of the global research and development costs while IDEAYA contributes 20%.
The financial implications of this collaboration are significant. Upon FDA acceptance of the IND, IDEAYA stands to gain a $7 million milestone payment, followed by a potential additional $10 million upon the initiation of Phase 1 clinical dose expansion. Furthermore, IDEAYA could earn up to $465 million in later-stage development and regulatory milestones. In the event of successful commercialization, the company could receive up to $475 million in commercial milestones, along with 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of IDE275.
With IDE275's promising preclinical data and strategic partnership with GSK, IDEAYA Biosciences is poised to make significant strides in the precision oncology landscape. The anticipated Phase 1 trial not only marks an important step for IDEAYA but also holds the potential to reshape treatment paradigms for patients facing challenging cancer diagnoses characterized by MSI-High tumors. As IDEAYA continues to expand its innovative pipeline, the oncology community is keenly watching how IDE275 will perform in clinical settings.
